Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Enoxaparin sodium; Rivaroxaban
- Indications Haemorrhage
- Focus Therapeutic Use
- Sponsors Portola Pharmaceuticals
- 14 Jun 2018 New trial record